相似文献
1
Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review.
Syst Rev. 2019 Jan 8;8(1):9. doi: 10.1186/s13643-018-0934-z.
2
Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis.
Pain Med. 2012 Sep;13(9):1121-30. doi: 10.1111/j.1526-4637.2012.01432.x. Epub 2012 Jul 30.
3
Emerging neuroprotective effects of N-palmitoylethanolamide besides its significant antinociceptive effects.
Pain Med. 2013 May;14(5):773-4. doi: 10.1111/pme.12118. Epub 2013 Apr 12.
4
5
Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis.
Pain Physician. 2016 Feb;19(2):11-24.
6
Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis.
Pain Physician. 2017 Jul;20(5):353-362.
7
A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis.
Inflammopharmacology. 2019 Jun;27(3):475-485. doi: 10.1007/s10787-019-00582-9. Epub 2019 Mar 29.
8
The palmitoylethanolamide family: a new class of anti-inflammatory agents?
Curr Med Chem. 2002 Mar;9(6):663-74. doi: 10.2174/0929867023370707.
9
Palmitoylethanolamide and hemp oil extract exert synergistic anti-nociceptive effects in mouse models of acute and chronic pain.
Pharmacol Res. 2021 May;167:105545. doi: 10.1016/j.phrs.2021.105545. Epub 2021 Mar 12.
10
Efficacy of ultra-micronized palmitoylethanolamide (um-PEA) in geriatric patients with chronic pain: study protocol for a series of N-of-1 randomized trials.
Trials. 2016 Jul 29;17:369. doi: 10.1186/s13063-016-1496-9.
引用本文的文献
1
The Effects of Cannabinoids on Ischemic Stroke-Associated Neuroinflammation: A Systematic Review.
J Neuroimmune Pharmacol. 2025 Feb 3;20(1):12. doi: 10.1007/s11481-025-10171-z.
2
A Decades-Long Journey of Palmitoylethanolamide (PEA) for Chronic Neuropathic Pain Management: A Comprehensive Narrative Review.
Pain Ther. 2025 Feb;14(1):81-101. doi: 10.1007/s40122-024-00685-4. Epub 2024 Dec 4.
3
Effectiveness of Palmitoylethanolamide (Levagen+) Compared to a Placebo for Reducing Pain, Duration, and Medication Use during Migraines in Otherwise Healthy Participants-A Double-Blind Randomised Controlled Study.
Pharmaceuticals (Basel). 2024 Jan 23;17(2):145. doi: 10.3390/ph17020145.
4
The Effect of Levagen+ (Palmitoylethanolamide) Supplementation on Symptoms of Allergic Rhinitis-A Double-Blind Placebo-Controlled Trial.
Nutrients. 2023 Nov 28;15(23):4940. doi: 10.3390/nu15234940.
5
Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence.
Pharmaceutics. 2022 Aug 11;14(8):1672. doi: 10.3390/pharmaceutics14081672.
6
The Protective Effects of Pre- and Post-Administration of Micronized Palmitoylethanolamide Formulation on Postoperative Pain in Rats.
Int J Mol Sci. 2020 Oct 18;21(20):7700. doi: 10.3390/ijms21207700.
本文引用的文献
1
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation.
Ann Intern Med. 2018 Oct 2;169(7):467-473. doi: 10.7326/M18-0850. Epub 2018 Sep 4.
2
The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms.
BMC Anesthesiol. 2017 Dec 19;17(1):171. doi: 10.1186/s12871-017-0461-9.
3
N-of-1 Randomized Trials of Ultra-Micronized Palmitoylethanolamide in Older Patients with Chronic Pain.
Drugs Aging. 2017 Dec;34(12):941-952. doi: 10.1007/s40266-017-0506-2.
4
Nonsurgical lumbar radiculopathies treated with ultramicronized palmitoylethanolamide (umPEA): A series of 100 cases.
Neurol Neurochir Pol. 2018 Jan-Feb;52(1):44-47. doi: 10.1016/j.pjnns.2017.11.002. Epub 2017 Nov 14.
5
The efficacy of an association of palmitoylethanolamide and alpha-lipoic acid in patients with chronic prostatitis/chronic pelvic pain syndrome: A randomized clinical trial.
Arch Ital Urol Androl. 2017 Mar 31;89(1):17-21. doi: 10.4081/aiua.2017.1.17.
6
The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.
Br J Pharmacol. 2017 Jun;174(11):1349-1365. doi: 10.1111/bph.13580. Epub 2016 Sep 29.
7
Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury.
Brain Behav Immun. 2011 Aug;25(6):1099-112. doi: 10.1016/j.bbi.2011.02.006. Epub 2011 Feb 25.
8
Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain.
Exp Neurol. 2010 Jul;224(1):48-55. doi: 10.1016/j.expneurol.2010.03.022. Epub 2010 Mar 29.
9
N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities.
Biochimie. 2010 Jun;92(6):724-7. doi: 10.1016/j.biochi.2010.01.006. Epub 2010 Jan 21.
10
Effects of palmitoylethanolamide on immunologically induced histamine, PGD2 and TNFalpha release from canine skin mast cells.
Vet Immunol Immunopathol. 2010 Jan 15;133(1):9-15. doi: 10.1016/j.vetimm.2009.06.011. Epub 2009 Jun 27.
Zotero 插件